PVX-001: open-source Covid-19 vaccine starts Phase 1 trial
PopVax has initiated a Phase 1 clinical trial for its open-source, broadly-protective COVID-19 vaccine candidate, PVX-001. The company plans to make the vaccine technology open-source once the trial concludes to facilitate global access.
Why it matters
The open-source approach to vaccine development represents a significant shift in pharmaceutical research models, potentially increasing accessibility to life-saving medicine.
Holy shit.
What a ride. What a fucking ride. What an insane fucking ride this has been.
I’ve waited 5 years to write these words: On 31 August 2026, the first two participants each received a dose of PVX-001, our broadly-protective COVID-19 vaccine candidate designed to protect against future variants of SARS-CoV-2 that may emerge, in a first-in-human Phase I clinical trial in Melbourne, Australia ( ACTRN12626000891325 ).
This trial, which will enroll a total of 36 healthy adult volunteers, is intended to assess the safety and tolerability of the vaccine candidate, while also providing early data on the magnitude and breadth of the immune response it elicits against multiple variants of SARS-CoV-2. As of 6 October 2026, we have enrolled and dosed 14 participants meeting our screening criteria, with no serious adverse events (SAEs) reported. Participant follow-up and safety monitoring are ongoing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in